The Rise of Biologics
Peak annual revenue of leading drug
Biologics now dominate pharmaceutical revenue, with Keytruda reaching $25B+ annually.
$29B+
peak annual revenue per drug
The Problem
We are in the era of biologic drugs. For 12 of the past 14 years, monoclonal antibodies have been the highest revenue drugs in the world — but they remain inaccessible to most patients.
Fewer Patients Reached
Despite record revenues, high costs mean the shift to biologics has dramatically reduced the number of patients treated.
30×
fewer patients treated
Costs Haven't Fallen
Unlike other technologies, biologics haven't seen the cost reductions that come with high-volume manufacturing.
2× vs 100×
cost reduction gap
Our Solution
We've spent 7 years industrialising cell culture for food, giving us a ~30× cost advantage over incumbent pharma manufacturers. Now we're applying this to biologics.
Aggregating Demand
Foundry model with standardised, optimised processes. Customers adapt products to fit our platform — not the other way around.
5 → 285 MT
projected annual volume by 2035
Factory as the Product
Unified design of hardware, software, operations, and AI to reduce CapEx and OpEx. Modular factories that deploy anywhere.
<$500K
vs $5-20M industry standard
Raw Materials at Scale
Cost-optimised supply chain with 70%+ cheaper raw materials. GMP quality media at a fraction of industry cost.
$1.15/L
vs $8-50/L industry standard
| Metric | Industry Standard | Federated Biologics |
|---|---|---|
| Cell Culture Cost | $50-100/L | ~$3-5/L |
| Production Line Cost | $5-20M | <$500K |
| Setup Timeline | 18-36 months | 5 months |
| Media Cost | $8-50/L | $1.15/L |